Last updated: June 5, 2026
Gilead v. Lupin (1:22-cv-00615) Litigation Summary and IP Analysis for Gilead Patents vs. Lupin Generic Entry
Executive summary: Gilead Sciences, Inc. v. Lupin Ltd., No. 1:22-cv-00615, filed in 2022, is a Hatch-Waxman patent infringement dispute tied to a Gilead-branded small-molecule product and Lupin’s proposed generic. The case posture, asserted patents, and the settlement or trial outcomes are not provided in the available record here, so a complete infringement-by-infringement, patent-expiration, and exclusivity risk analysis cannot be produced accurately.
What patents were asserted in Gilead Sciences v. Lupin Ltd. 1:22-cv-00615?
Featured snippet: The asserted-patent list (Orange Book patents-in-suit) for 1:22-cv-00615 is required to summarize claims and defenses, but it is not available in the provided information.
Which patent numbers and assignees drive the infringement theory?
Key elements for an IP litigation summary include:
- Asserted US patent numbers
- Patent assignees (Gilead, affiliates, co-owners)
- Claim categories (composition, formulation, method-of-use, manufacturing, kit, or polymorph)
- Reference product and Orange Book coverage
No asserted-patent identifiers are included in the supplied input.
What claim scope did the complaint target (composition vs. method-of-use)?
A defensible claim-scope analysis requires:
- Independent claim text or claim chart summaries
- The accused product description (e.g., strength, dosage form, salt/crystal form)
- The legal basis (literal infringement vs. equivalents)
Those facts are not present.
What is the procedural timeline for 1:22-cv-00615 (filing, service, motions, trial)?
Featured snippet: A procedural timeline requires docket events. The input does not include filings or docket entries.
Key litigation milestones typically summarized
To produce an accurate litigation analysis, the docket would need:
- Complaint filing date
- Answer and defenses (invalidity, non-infringement, unenforceability)
- Rule 12/Rule 56 motions
- Markman, claim construction (if any)
- Scheduling orders, discovery, expert reports
- Trial date and dispositive rulings
None of these are included.
What settlement terms (if any) were reached in Gilead v. Lupin 1:22-cv-00615?
Featured snippet: Settlement analysis requires a documented settlement agreement or docket orders specifying:
- Stated effective date
- Prohibition period (carve-outs for design changes, launch at risk carve-outs)
- License terms (if any)
- Dismissal with/without prejudice
- Mutual releases
- Amended dismissal tied to specific patents
The supplied input includes no settlement details.
How do Paragraph IV filings and FDA approval status affect 1:22-cv-00615?
Featured snippet: Paragraph IV and FDA status drive launch timing, but the RLD, ANDA application number, and FDA milestones are not provided.
Which FDA application was at issue (ANDA/BLA, submission type)?
A compliant analysis needs:
- ANDA number
- Applicant name and manufacturing sites
- Drug product and strengths
- Paragraph IV certification details to specific Orange Book patents
- FDA action timeline (tentative approval, approval date, refusal, forfeiture)
No FDA application identifiers are included.
Which generic entry risks existed for Lupin after 1:22-cv-00615?
Featured snippet: Entry risk depends on remaining patent life and exclusivity, and on which patents were invalidated or not infringed. Those determinations are not provided.
What patent-expiration and exclusivity dates controlled launch?
A litigation risk model typically maps:
- Earliest non-expired asserted patent date
- Secondary barriers (method-of-use patents, exclusivity listings, pediatrics, data exclusivity)
- Future exclusivity events (new use, change in labeling, managed entry agreements)
No expiration/exclusivity dates or Orange Book listing data are included.
How strong was Gilead’s patent estate in this case (validity and enforceability positions)?
Featured snippet: Strength assessment requires:
- Court rulings on invalidity or non-infringement
- Enforceability findings (inequitable conduct, prosecution history estoppel, patent office estoppel)
- Claim construction outcomes
No rulings or claim construction outcomes are provided.
Common validity defenses to evaluate (and missing here)
- 35 U.S.C. § 102 novelty
- 35 U.S.C. § 103 obviousness (prior art mapping)
- 35 U.S.C. § 112 written description, enablement, indefiniteness
- Lack of enablement for claimed scope
- Indefiniteness tied to claim terms
- Improper dependences/claiming errors
- Nonstatutory obviousness-type double patenting
No such content is included in the prompt.
How does Gilead’s litigation posture compare with other challengers to Gilead products (same family, same Orange Book)?
Featured snippet: Comparisons require a list of other Hatch-Waxman cases for the same reference product and overlapping patents. No product identity or patent family identifiers are provided.
Comparison dimensions that require docket and patent mapping
- Whether other defendants settled or litigated to judgment
- Whether courts invalidated key claims
- Whether settlements include “no-AG” covenants, covenants not to sue, or cross-licenses
- Whether design-around succeeded
Not available.
What manufacturing, formulation, or method-of-use design-arounds were at issue?
Featured snippet: Design-around analysis depends on accused product details and expert reports, neither of which are included.
Typical design-around vectors
- Different salt form, polymorph, or particle size distribution
- Different excipient system affecting dissolution
- Alternative dosing regimen to avoid method-of-use claims
- Manufacturing process changes targeting process-method claims
No accused formulation or method is included.
What is the Orange Book status of Gilead vs. Lupin’s proposed generic in this dispute?
Featured snippet: Orange Book status requires listing-level detail (patent numbers, status: expired, expiring, listed for specific dosage forms). The prompt provides none.
Which patents were listed as “to the drug” and which were litigated?
A complete Orange Book summary would include:
- Patent numbers listed to the RLD
- Expiration dates
- Exclusivity codes
- Listed dosage forms
- Specific patents certified under Paragraph IV
No listing data is included.
Key Takeaways
- Case identification: Gilead Sciences, Inc. v. Lupin Ltd., No. 1:22-cv-00615.
- Missing for a complete litigation and IP analysis: asserted patent list, docket milestones, rulings, and settlement terms are not included in the provided input.
- Actionable conclusion: a patent-expiration, claim-scope, and infringement-risk analysis cannot be produced from the supplied information without introducing inaccuracies.
FAQs
- What does a typical Paragraph IV certification look like in a Gilead Hatch-Waxman case?
- How do method-of-use patents change generic launch timing versus composition patents?
- What court outcomes most directly reduce Gilead’s ability to block FDA approval?
- How do design-around strategies usually target salt form, polymorph, or dissolution profiles?
- What settlement clauses most commonly govern “at-risk” launch timing in ANDA litigations?
References
- Gilead Sciences, Inc. v. Lupin Ltd., No. 1:22-cv-00615 (court docket information not provided in the input).
